NURIX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.59 USD | +7.73% |
|
+22.80% | +60.76% |
| May. 14 | Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target | MT |
| Apr. 12 | Sector Update: Health Care Stocks Steady Pre-Bell Friday | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 71.27M | Sales 2025 * | 66.83M | Capitalization | 984M |
|---|---|---|---|---|---|
| Net income 2024 * | -171M | Net income 2025 * | -221M | EV / Sales 2024 * | 9.65 x |
| Net cash position 2024 * | 297M | Net cash position 2025 * | 297M | EV / Sales 2025 * | 10.3 x |
| P/E ratio 2024 * |
-5.57
x | P/E ratio 2025 * |
-4.97
x | Employees | 284 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.82% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +7.73% | ||
| 1 week | +22.80% | ||
| Current month | +38.02% | ||
| 1 month | +17.83% | ||
| 3 months | +68.09% | ||
| 6 months | +163.33% | ||
| Current year | +60.76% |
1 week
13.55
16.84
1 month
11.9016.84
Current year
7.6518.12
1 year
4.2218.12
3 years
4.2237.43
5 years
4.2252.38
10 years
4.2252.38
| Managers | Title | Age | Since |
|---|---|---|---|
Arthur Sands
CEO | Chief Executive Officer | 62 | 14-09-17 |
Hans van Houte
DFI | Director of Finance/CFO | 58 | 14-12-31 |
| Chief Tech/Sci/R&D Officer | - | 21-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Judith Reinsdorf
BRD | Director/Board Member | 60 | 21-09-30 |
Paul Silva
BRD | Director/Board Member | 58 | 21-09-30 |
Arthur Sands
CEO | Chief Executive Officer | 62 | 14-09-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.70% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 16.59 | +7.73% | 3,038,647 |
| 24-05-16 | 15.4 | -3.14% | 584,716 |
| 24-05-15 | 15.9 | +6.35% | 979,161 |
| 24-05-14 | 14.95 | +7.25% | 1,492,411 |
| 24-05-13 | 13.94 | +3.18% | 326,778 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Calendar
2024-05-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.59
USD
Average target price
24.67
USD
Spread / Average Target
+48.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +60.76% | 913M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- NRIX Stock
